查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2021685

宠物药品市场预测至2034年－按产品类型、目标动物、给药途径、通路、应用和地区分類的全球分析

Pet Pharmaceuticals Market Forecasts to 2034 - Global Analysis By Product Type, Animal Type, Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 预测，全球宠物药品市场预计到 2026 年将达到 180 亿美元，并在预测期内以 8.5% 的复合年增长率增长，到 2034 年将达到 350 亿美元。

宠物药品是指用于预防、诊断和治疗伴侣动物疾病的药物，包括疫苗、感染疾病物、驱虫药、止痛药和特殊疗法。宠物饲养量的增加、宠物医疗保健支出的增长以及兽医学的进步是推动该市场发展的因素。监管确保了药物的安全性和有效性。人们对预防医学和慢性病管理的日益重视，正在扩大对药物解决方案的需求，使该领域成为更广泛的动物保健行业的重要组成部分。

宠物饲养量和医疗保健支出增加

随着宠物在世界各地的家庭中日益被视为家庭成员，对兽医服务的需求也随之增长。人们对预防保健和维持健康意识的提高，促进了药品供应。各国政府和非政府组织正在推广疫苗接种和寄生虫防治项目，并提高了市场认知度。可支配收入的增加，使饲主能够为宠物投资高品质的医疗保健方案。製药公司正在拓展产品线，以满足从伴侣动物到牲畜等各类宠物的多样化需求。

监管核准的复杂性

宠物药品必须经过严格的测试和认证，以确保其安全性和有效性。这个过程会增加成本，并可能延迟产品上市，尤其对于中小企业而言更是如此。法规结构的区域差异进一步增加了全球製造商面临的复杂性。合规要求往往会限制创新并减缓商业化进程。企业面临着如何在快速上市和严格的核准标准之间取得平衡的挑战。随着监管力道的加大，监管的复杂性将继续限制宠物药品产业的成长速度。

拓展医疗保健解决方案

疫苗、营养补充品和驱虫药等预防性产品在宠物饲主中越来越受欢迎。人们对长期健康益处的认识不断提高，推动了预防保健的需求。各国政府都在支持预防性项目，以降低伴侣动物和牲畜的疾病发生率。製药公司也加大研发投入，开发先进的预防性解决方案。与兽医诊所和宠物护理机构的合作，也促进了这些产品的普及。

严格的监理合规要求

世界各国政府对宠物药品的生产、标籤和分销都制定了严格的标准。违反这些标准可能导致产品召回、罚款和声誉损害。与大型企业相比，中小企业往往难以满足这些要求。区域监管的变化也为长期规划带来了不确定性。合规成本会增加营运负担并降低盈利。未能确保合规性会使公司面临失去市场份额和在宠物保健行业信誉的风险。

新冠疫情的影响：

新冠疫情对宠物药品市场产生了复杂的影响。初期，供应链中断减缓了动物用药品的生产和分销。然而，疫情封锁期间宠物饲养量的增加提振了对宠物保健产品的需求。饲主寻求预防和健康维护方案，以确保宠物在疫情期间的安全。远端医疗和线上零售平台成为药品分销的重要管道。世界各国政府将动物健康纳入更广泛的公共卫生措施中，并予以优先考虑。总而言之，新冠疫情改变了消费者的行为，同时也凸显了宠物医疗保健产业韧性和适应性的重要性。

在预测期内，驱虫药市场预计将占据最大的市场份额。

由于驱虫药在预防保健中的广泛应用，预计在预测期内，驱虫药将占据最大的市场份额。驱虫药能够保护宠物免受跳蚤、蜱虫和其他寄生虫的侵害，确保它们的长期健康和安全。配方方面的持续创新正在提高其有效性和便利性。各国政府正透过宣传宣传活动和补助来支持寄生虫控制计画。兽医诊所也越来越多地将驱虫药作为日常护理的一部分。零售商正在扩大产品范围，以满足市场对这些产品的持续需求。

在预测期内，线上零售领域预计将呈现最高的复合年增长率。

在预测期内，由于消费者对更便利的购物体验的需求不断增长，预计线上零售领域将呈现最高的成长率。宠物饲主越来越多地透过电商平台购买药品。线上通路提供更广泛的产品选择、更具竞争力的价格以及送货上门服务。各国政府正透过基础建设和政策框架支持数位零售的发展。製药公司与线上平台的合作正在提升品牌知名度并促进销售。数位行销宣传活动正在增强消费者参与度和品牌忠诚度。

市占率最大的地区：

在预测期内，由于强劲的消费者需求和先进的兽医基础设施，北美预计将占据最大的市场份额。美国在宠物医疗保健创新方面处于领先地位，并拥有种类繁多的药品。政府支持的动物健康计画确保了对预防和治疗方案的稳定需求。知名品牌和零售商正在推动宠物药品的商业化。对高级产品和有机产品日益增长的需求正在促使产品系列进行重组。投资者对以永续性为重点的项目的信心进一步推动了产品的普及。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于快速的都市化和不断增长的可支配收入。中国、印度和日本等国家对宠物保健产品的需求强劲。政府主导的促进动物健康和福利的措施正在推动宠物保健产品的普及。本土Start-Ups正凭藉经济高效且创新的解决方案进入市场，这些方案均针对当地需求量身定制。电子商务和现代兽医服务的扩张进一步推动了市场成长。新兴市场消费者对预防性医疗保健意识的提高正在改变他们的消费偏好。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球宠物药品市场：依产品类型划分

  • 感染疾病物
  • 抗发炎药
  • 杀虫剂
  • 疫苗
  • 疼痛管理药物
  • 其他产品类型

第六章 全球宠物药品市场：依动物类型划分

  • 狗
  • 猫
  • 马
  • 鸟
  • 其他动物类型

第七章：全球宠物药品市场：依给药途径划分

  • 口服
  • 注射药物
  • 外用
  • 其他给药途径

第八章 全球宠物药品市场：依通路划分

  • 动物诊所
  • 药局
  • 线上零售
  • 宠物专卖店
  • 其他分销管道

第九章 全球宠物药品市场：依应用划分

  • 感染疾病
  • 慢性病
  • 寄生虫感染疾病
  • 疼痛管理
  • 疫苗接种
  • 其他用途

第十章：全球宠物药品市场：依地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Merck Animal Health
  • Boehringer Ingelheim Animal Health
  • Ceva Sante Animale
  • Virbac SA
  • Dechra Pharmaceuticals PLC
  • Vetoquinol SA
  • IDEPet Pharmaceuticals Laboratories, Inc.
  • Heska Corporation
  • Phibro Animal Health Corporation
  • Neogen Corporation
  • Bayer AG（Animal Health division）
  • Sanofi（Animal Health legacy）
  • Zydus Animal Health
  • Intas Pharmaceuticals
Product Code: SMRC35097

According to Stratistics MRC, the Global Pet Pharmaceuticals Market is accounted for $18 billion in 2026 and is expected to reach $35 billion by 2034 growing at a CAGR of 8.5% during the forecast period. Pet Pharmaceuticals refer to medicinal products used to prevent, diagnose, and treat diseases in companion animals. These include vaccines, anti-infectives, parasiticides, pain management drugs, and specialty therapeutics. The market is driven by rising pet ownership, increased spending on pet healthcare, and advancements in veterinary medicine. Regulatory oversight ensures safety and efficacy. Growing awareness of preventive care and chronic disease management is expanding demand for pharmaceutical solutions, making this segment a critical part of the broader animal healthcare industry.

Market Dynamics:

Driver:

Rising pet ownership and healthcare spending

Families worldwide are treating pets as integral members of households, leading to higher demand for veterinary care. Growing awareness of preventive healthcare and wellness is reinforcing pharmaceutical adoption. Governments and NGOs are promoting vaccination and parasite control programs, strengthening market visibility. Rising disposable incomes are enabling owners to invest in premium healthcare solutions for pets. Pharmaceutical companies are expanding product ranges to cater to diverse pet needs, from companion animals to livestock.

Restraint:

Regulatory approval complexities

Pet pharmaceuticals must undergo rigorous testing and certification to ensure safety and efficacy. This processes increase costs and delay product launches, particularly for smaller firms. Variations in regulatory frameworks across regions add complexity for global manufacturers. Compliance requirements often limit innovation and slow down commercialization. Companies face challenges in balancing speed-to-market with strict approval standards. As oversight intensifies, regulatory complexities will continue to restrict the pace of growth in the pet pharmaceuticals sector.

Opportunity:

Expansion in preventive healthcare solutions

Preventive products such as vaccines, supplements, and parasiticides are gaining traction among pet owners. Rising awareness of long-term health benefits is driving demand for preventive care. Governments are supporting preventive programs to reduce disease incidence in companion and farm animals. Pharmaceutical companies are investing in R&D to develop advanced preventive solutions. Partnerships with veterinary clinics and pet care providers are reinforcing adoption.

Threat:

Stringent regulatory compliance requirements

Governments enforce strict standards for manufacturing, labeling, and distribution of pet pharmaceuticals. Non-compliance can lead to recalls, fines, and reputational damage. Smaller firms often struggle to meet these requirements compared to established corporations. Regulatory changes across regions add uncertainty to long-term planning. Compliance costs increase operational burdens and reduce profitability. Without robust adherence to standards, companies risk losing market share and credibility in the pet healthcare industry.

Covid-19 Impact:

The Covid-19 pandemic had mixed effects on the pet pharmaceuticals market. Supply chain disruptions initially slowed production and distribution of veterinary medicines. However, rising pet adoption during lockdowns boosted demand for healthcare products. Owners sought preventive and wellness solutions to ensure pet safety during the pandemic. Telemedicine and online retail platforms became vital channels for pharmaceutical distribution. Governments emphasized animal health as part of broader public health initiatives. Overall, Covid-19 reshaped consumer behavior while reinforcing the importance of resilience and adaptability in the pet healthcare sector.

The parasiticides segment is expected to be the largest during the forecast period

The parasiticides segment is expected to account for the largest market share during the forecast period as these products are widely used for preventive care. Parasiticides protect pets against fleas, ticks, and worms, ensuring long-term health and safety. Continuous innovation in formulations is improving efficacy and convenience. Governments are supporting parasite control programs through awareness campaigns and subsidies. Veterinary clinics are increasingly recommending parasiticides as part of routine care. Retailers are expanding assortments to meet consistent demand for these products.

The online retail segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online retail segment is predicted to witness the highest growth rate due to rising demand for convenience and accessibility. Pet owners are increasingly purchasing pharmaceuticals through e-commerce platforms. Online channels offer wider product variety, competitive pricing, and doorstep delivery. Governments are supporting digital retail expansion through infrastructure and policy frameworks. Partnerships between pharmaceutical companies and online platforms are driving visibility and sales. Digital marketing campaigns are reinforcing consumer engagement and brand loyalty.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong consumer demand and advanced veterinary infrastructure. The U.S. leads in pet healthcare innovation, with a wide range of pharmaceutical products available. Government-backed animal health programs ensure steady demand for preventive and therapeutic solutions. Established brands and retailers are driving commercialization of pet pharmaceuticals. Rising demand for premium and organic variants is reshaping product portfolios. Investor confidence in sustainability-focused projects is further strengthening adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid urbanization and rising disposable incomes. Countries such as China, India, and Japan are witnessing strong demand for pet healthcare products. Government-backed initiatives promoting animal health and welfare are boosting adoption. Local startups are entering the market with cost-effective and innovative solutions tailored to regional needs. Expansion of e-commerce and modern veterinary services is further supporting growth. Rising awareness of preventive healthcare is reshaping consumer preferences in emerging economies.

Key players in the market

Some of the key players in Pet Pharmaceuticals Market include Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health, Boehringer Ingelheim Animal Health, Ceva Sante Animale, Virbac S.A., Dechra Pharmaceuticals PLC, Vetoquinol S.A., IDEPet Pharmaceuticals Laboratories, Inc., Heska Corporation, Phibro Animal Health Corporation, Neogen Corporation, Bayer AG (Animal Health division), Sanofi (Animal Health legacy), Zydus Animal Health and Intas Pharmaceuticals.

Key Developments:

In February 2025, Elanco announced a major agreement with South Dakota-based Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle, leveraging Medgene's innovative vaccine platform technology. This partnership strengthens Elanco's diverse dairy portfolio and advances its "One Health" platform, addressing a critical need as the HPAI virus had spread to nearly 1,000 dairy herds across the U.S.

In December 2024, Zoetis announced the global launch of its new point-of-care hematology analyzer, which uses AI to provide accurate complete blood count (CBC) analysis in minutes. First installations were planned for early 2025 in the USA, Canada, UK, and other key markets.

Product Types Covered:

  • Anti-Infectives
  • Anti-Inflammatory Drugs
  • Parasiticides
  • Vaccines
  • Pain Management Drugs
  • Other Product Types

Animal Types Covered:

  • Dogs
  • Cats
  • Horses
  • Birds
  • Other Animal Types

Route of Administration Covered:

  • Oral
  • Injectable
  • Topical
  • Other Routes of Administration

Distribution Channels Covered:

  • Veterinary Clinics
  • Pharmacies
  • Online Retail
  • Pet Specialty Stores
  • Other Distribution Channels

Applications Covered:

  • Infectious Diseases
  • Chronic Conditions
  • Parasitic Infections
  • Pain Management
  • Immunization
  • Other Applications

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Pharmaceuticals Market, By Product Type

  • 5.1 Anti-Infectives
  • 5.2 Anti-Inflammatory Drugs
  • 5.3 Parasiticides
  • 5.4 Vaccines
  • 5.5 Pain Management Drugs
  • 5.6 Other Product Types

6 Global Pet Pharmaceuticals Market, By Animal Type

  • 6.1 Dogs
  • 6.2 Cats
  • 6.3 Horses
  • 6.4 Birds
  • 6.5 Other Animal Types

7 Global Pet Pharmaceuticals Market, By Route of Administration

  • 7.1 Oral
  • 7.2 Injectable
  • 7.3 Topical
  • 7.4 Other Routes of Administration

8 Global Pet Pharmaceuticals Market, By Distribution Channel

  • 8.1 Veterinary Clinics
  • 8.2 Pharmacies
  • 8.3 Online Retail
  • 8.4 Pet Specialty Stores
  • 8.5 Other Distribution Channels

9 Global Pet Pharmaceuticals Market, By Application

  • 9.1 Infectious Diseases
  • 9.2 Chronic Conditions
  • 9.3 Parasitic Infections
  • 9.4 Pain Management
  • 9.5 Immunization
  • 9.6 Other Applications

10 Global Pet Pharmaceuticals Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Zoetis Inc.
  • 13.2 Elanco Animal Health Incorporated
  • 13.3 Merck Animal Health
  • 13.4 Boehringer Ingelheim Animal Health
  • 13.5 Ceva Sante Animale
  • 13.6 Virbac S.A.
  • 13.7 Dechra Pharmaceuticals PLC
  • 13.8 Vetoquinol S.A.
  • 13.9 IDEPet Pharmaceuticals Laboratories, Inc.
  • 13.10 Heska Corporation
  • 13.11 Phibro Animal Health Corporation
  • 13.12 Neogen Corporation
  • 13.13 Bayer AG (Animal Health division)
  • 13.14 Sanofi (Animal Health legacy)
  • 13.15 Zydus Animal Health
  • 13.16 Intas Pharmaceuticals

List of Tables

  • Table 1 Global Pet Pharmaceuticals Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pet Pharmaceuticals Market, By Product Type (2023-2034) ($MN)
  • Table 3 Global Pet Pharmaceuticals Market, By Anti-Infectives (2023-2034) ($MN)
  • Table 4 Global Pet Pharmaceuticals Market, By Anti-Inflammatory Drugs (2023-2034) ($MN)
  • Table 5 Global Pet Pharmaceuticals Market, By Parasiticides (2023-2034) ($MN)
  • Table 6 Global Pet Pharmaceuticals Market, By Vaccines (2023-2034) ($MN)
  • Table 7 Global Pet Pharmaceuticals Market, By Pain Management Drugs (2023-2034) ($MN)
  • Table 8 Global Pet Pharmaceuticals Market, By Other Product Types (2023-2034) ($MN)
  • Table 9 Global Pet Pharmaceuticals Market, By Animal Type (2023-2034) ($MN)
  • Table 10 Global Pet Pharmaceuticals Market, By Dogs (2023-2034) ($MN)
  • Table 11 Global Pet Pharmaceuticals Market, By Cats (2023-2034) ($MN)
  • Table 12 Global Pet Pharmaceuticals Market, By Horses (2023-2034) ($MN)
  • Table 13 Global Pet Pharmaceuticals Market, By Birds (2023-2034) ($MN)
  • Table 14 Global Pet Pharmaceuticals Market, By Other Animal Types (2023-2034) ($MN)
  • Table 15 Global Pet Pharmaceuticals Market, By Route of Administration (2023-2034) ($MN)
  • Table 16 Global Pet Pharmaceuticals Market, By Oral (2023-2034) ($MN)
  • Table 17 Global Pet Pharmaceuticals Market, By Injectable (2023-2034) ($MN)
  • Table 18 Global Pet Pharmaceuticals Market, By Topical (2023-2034) ($MN)
  • Table 19 Global Pet Pharmaceuticals Market, By Other Routes of Administration (2023-2034) ($MN)
  • Table 20 Global Pet Pharmaceuticals Market, By Distribution Channel (2023-2034) ($MN)
  • Table 21 Global Pet Pharmaceuticals Market, By Veterinary Clinics (2023-2034) ($MN)
  • Table 22 Global Pet Pharmaceuticals Market, By Pharmacies (2023-2034) ($MN)
  • Table 23 Global Pet Pharmaceuticals Market, By Online Retail (2023-2034) ($MN)
  • Table 24 Global Pet Pharmaceuticals Market, By Pet Specialty Stores (2023-2034) ($MN)
  • Table 25 Global Pet Pharmaceuticals Market, By Other Distribution Channels (2023-2034) ($MN)
  • Table 26 Global Pet Pharmaceuticals Market, By Application (2023-2034) ($MN)
  • Table 27 Global Pet Pharmaceuticals Market, By Infectious Diseases (2023-2034) ($MN)
  • Table 28 Global Pet Pharmaceuticals Market, By Chronic Conditions (2023-2034) ($MN)
  • Table 29 Global Pet Pharmaceuticals Market, By Parasitic Infections (2023-2034) ($MN)
  • Table 30 Global Pet Pharmaceuticals Market, By Pain Management (2023-2034) ($MN)
  • Table 31 Global Pet Pharmaceuticals Market, By Immunization (2023-2034) ($MN)
  • Table 32 Global Pet Pharmaceuticals Market, By Other Applications (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.